TELOTelomir Pharmaceuticals, Inc. Common Stock

$46M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$1M

Net Income

-$2M

EPS (Diluted)

$-0.05

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$33,577

Free Cash Flow

-$33,577

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$6M

Total Liabilities

$2M

Stockholders' Equity

$4M

Cash & Equivalents

$14,629

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$1M	-$70,064	-1935.8%
Net Income	-$2M	-$70,064	-2112.8%

TELO Q2 2023 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena